Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae maintains a 'Buy' rating on Sonnet BioTherapeutics (NASDAQ:SONN) but has lowered the price target from $14 to $12.
August 16, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sonnet BioTherapeutics' price target has been lowered from $14 to $12 by Chardan Capital, though the 'Buy' rating is maintained.
The news directly pertains to Sonnet BioTherapeutics as Chardan Capital has lowered its price target for the company. However, the 'Buy' rating is maintained which indicates a positive outlook for the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100